A Prospective Study of Response-adapted Low-dose Radiotherapy Combined With Orelabrutinib for Localized Mucosa-associated Lymphoid Tissue Extranodal Marginal Zone Lymphoma

NCT07705308 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

140

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)

Interventions

RADIATION: Radiation (Very low dose)
RADIATION: Radiation (Standard)

Sponsor

Ruijin Hospital